People with sickle cell disease are largely absent from the trials that built the evidence base for these drugs, and 84.5% of this cohort were Black — a group underrepresented in almost every study this site covers, including the access picture in uptake after a heart attack or stroke. A retrospective analysis matched 1,391 pairs who had both sickle cell disease and type 2 diabetes and followed them for a year [1].
The cardiovascular findings are roughly what this drug class produces elsewhere. Major adverse cardiovascular events came in at a hazard ratio of 0.61 (95% CI 0.49–0.76), and stroke at 0.47 (95% CI 0.23–0.97).
The novel result is the one specific to the disease. Vaso-occlusive crises — the painful episodes that define sickle cell disease and drive most of its hospital admissions — occurred 36% less often among GLP-1 users (HR 0.64, 95% CI 0.45–0.91). That is not a cardiovascular benefit restated; it is a claim about the mechanism of the underlying disease, and there is no obvious precedent for it in this drug class. Whether an anti-inflammatory route could plausibly carry such an effect is the same open question raised by the inflammation substudy.
Two limits shape how far any of this travels. Everyone in the study had type 2 diabetes as well as sickle cell disease, which is an unusual combination and not the typical patient with either condition. And the stroke interval, at 0.23 to 0.97, is the kind that excludes 1 by a margin thin enough that a modest amount of unmeasured confounding would erase it — a caution that applies with equal force to the glaucoma comparison, where the upper bound was 0.96.
What makes this worth reporting despite those limits is that the alternative is nothing. Rare-disease populations rarely accumulate enough participants for a trial, and a matched cohort of 1,391 pairs is a substantial body of evidence by the standards of the field it sits in. A result that would be preliminary in type 2 diabetes is, here, among the better evidence available — which is also true of the disease-specific findings in the Crohn's disease cohort.